A novel approach to enhance re-epithialisation speed by disrupting dimeric 14-3-3 protein.
Current wound healing therapies rely on one of three separate approaches:
Our novel approach to facilitate rapid wound healing takes advantage of a mechanism we have newly discovered to enhance mitogenic signalling and promote endogenous ECM production, using inhibition of 14-3-3.
This approach uses a novel class of 14-3-3 inhibitors that disrupts 14-3-3 dimers in a manner that is not reliant on competing with the binding of 14-3-3’s phospho-serine containing client proteins.
14-3-3 proteins act as adaptor proteins to regulate signalling pathways that promote cell proliferation and cell survival, acting as obligate dimers. The 14-3-3 isoform is one of the dominant isoforms expressed in skin and is upregulated significantly in chronic, non-healing wounds such as diabetic ulcers. Furthermore, mice deficient in 14-3-3 exhibited rapid wound healing that was 3-fold faster than that observed in normal control mice. 14-3-3 acts to restrain the activation of Rho-ROCK signalling at wound margins, thereby moderating the production and remodeling of extra-cellular matrix (ECM). Re-establishment of damaged ECM is a key requirement in wound healing as it performs a scaffolding role to support re-epithelialization of the wound and also initiates mechanical signalling pathways required for epidermal cell proliferation. Consequently, inhibiting 14-3-3 activity is an attractive approach to enhance wound healing in chronic wounds.
We used a novel class of molecules that mimic the binding of sphingosine lipid to 14-3-3 at the dimer interface, thereby permitting kinases to access a buried phosphorylation site, phosphorylation of which inhibits 14-3-3 dimerisation. Our studies have revealed that inhibiting 14-3-3 by using these novel molecules accelerates wound healing in a murine model, phenocopying observations in 14-3-3 deficient animals.
We are currently developing pharmacological inhibition of 14-3-3 with the intent of establishing a novel modality for the treatment of chronic wounds.
PCT patent application filed for ‘Modulators of 14-3-3 Functionality and Uses Thereof’ as specification PCT/AU2015000605.
We are seeking co-development partners and technology licensees for the further development of this opportunity
Some of these cookies are essential for the website to function correctly, while others may collect your personal information. In some cases, the personal information collected by our cookies may be shared with third party service providers.
For details about the categories of cookies that we use, and to set your cookie preferences, please select ‘More information’ before you continue. For an overview see our Privacy Statement, or review our Privacy Policy in full.